AbbVie Inc (NYSE:ABBV)

66.07
Delayed Data
As of Apr 24
 +1.82 / +2.83%
Today’s Change
48.95
Today|||52-Week Range
70.76
+0.96%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$102.3B

Company Description

AbbVie, Inc. is a research-based biopharmaceutical company. It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products. The company's products are used to treat rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis complications, low testosterone, thyroid disease, Parkinson's disease, ulcerative colitis, and complications associated with chronic kidney disease, among other indications. It also has a pipeline of new medicines, including various compounds or indications in Phase II or Phase III development across such medical specialties as immunology, renal care, hepatitis C, women's health, oncology, and neuroscience, including multiple sclerosis and Alzheimer's disease. The company was founded on April 10, 2012 and is headquartered in North Chicago, IL.

Contact Information

AbbVie, Inc.
1 North Waukegan Road
North Chicago Illinois 60064-6400
P:(847) 932-7900
Investor Relations:
(847) 935-6722

Employees

Shareholders

Other institutional36.36%
Mutual fund holders35.87%
Individual stakeholders0.12%

Top Executives

Richard A. GonzalezChairman & Chief Executive Officer
Azita Saleki-GerhardtSenior Vice President-Operations
William J. ChaseChief Financial Officer & Executive Vice President
Michael E. SeverinoChief Scientific Officer & Executive VP
Thomas A. HurwichVice President & Controller

To view my watchlist

Not a member yet?

Sign up now for a free account